Singleversustandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial

How we manage autologous stem cell transplantation for patients with multiple myeloma

(2014) M. A. Gertz et al.   BLOOD

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

(2014) M. Engelhardt et al.   HAEMATOLOGICA

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

(2010) Bart Barlogie et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Methods for Equivalence and Noninferiority Testing

(2009) Gisela Tunes da Silva et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

(2009) A. Palumbo et al.   BLOOD

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis

(2009) A. Kumar et al.   JNCI-Journal of the National Cancer Institute